- Roche’s Phase III STARGLO study demonstrates Columvi significantly extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
- Roche four-in-one molecular test for SARS-CoV-2, Influenza A/B viruses and RSV receives U.S. FDA Emergency Use Authorization
- European Commission approves Roche’s Alecensa as the first and only targeted adjuvant treatment for people with ALK-positive early-stage lung cancer
- Five-year data for Roche’s Evrysdi show the majority of treated children with a severe form of spinal muscular atrophy (SMA) achieved or maintained the ability to sit, stand or walk
- FDA grants Priority Review to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
- Wechsel in der erweiterten Konzernleitung von Roche
- Changes to the Roche Enlarged Corporate Executive Committee
- Roche granted FDA Breakthrough Device Designation for blood test measuring Lp(a) – a key marker for hereditary cardiovascular risk
- FDA grants Breakthrough Therapy Designation to Roche’s inavolisib for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation
- [Ad hoc announcement pursuant to Art. 53 LR] Roche reports positive Phase I results for its dual GLP-1/GIP receptor agonist CT-388 in people with obesity
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 31.40 |
---|---|
High | 32.20 |
Low | 31.30 |
Bid | 32.10 |
Offer | 32.70 |
Previous close | 31.80 |
Average volume | 305.60 |
---|---|
Shares outstanding | 6.47bn |
Free float | 328.26m |
P/E (TTM) | 17.26 |
Market cap | 227.31bn USD |
EPS (TTM) | 2.01 USD |
Data delayed at least 15 minutes, as of Jun 14 2024 18:32 BST.
More ▼